SEC Form 4 · accession 0001209191-17-005571
Kura Oncology, Inc. · KURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pingda Ren
Officer — SVP-Chemistry&Pharma Sciences
Period of report
Jan 23, 2017
Accepted (ET)
Jan 25, 2017 · 5:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001422143
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase common stockF1 | $6.15 | Jan 23, 2017 | A | 55,000 | A | — | Jan 22, 2027 | Common Stock | 55,000 | 55,000 | D |
Explanation of responses
- F1This option vests in 48 equal monthly installments commencing on the grant date.